No recent analyst price targets found for LBTSF.
Latest News for LBTSF
Almirall, S.A. (ALMRY) Q2 2026 Earnings Call Transcript
Almirall, S.A. (ALMRY) Q2 2026 Earnings Call Transcript
Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older
BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that the European Medicines Agency (EMA) has accepted the submission of the extension of the Marketing Authorisation Application (MAA) of Ebglyss® (lebrikizumab) for the treatment of children and adolescents aged 6 months to
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LBTSF.
Senate Trading
No Senate trades found for LBTSF.
U.S. House Trading
No House trades found for LBTSF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.